Prioritizing pharmacogenetic research: A value of information analysis of CYP2D6 testing to guide breast cancer treatment

Value in Health

Volumn 14, Issue 8, 2011, Pages 989-1001

  Woods, Beth ^a   Veenstra, David ^b   Hawkins, Neil ^a,c  

^a ICON PLC   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

CYP2D6; decision modeling; pharmacogenetics; tamoxifen; value of information

Indexed keywords

ANASTROZOLE; CYTOCHROME P450 2D6; TAMOXIFEN;

ARTICLE; BREAST CANCER; COST EFFECTIVENESS ANALYSIS; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNCERTAINTY; UNITED KINGDOM; WILD TYPE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2D6; DECISION SUPPORT TECHNIQUES; ECONOMICS, PHARMACEUTICAL; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; MARKOV CHAINS; NITRILES; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TAMOXIFEN; TRIAZOLES;

EID: 82955239865     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.05.048     Document Type: Article

References (60)

1. L.P. Garrison, D.L. Veenstra, R.J. Carlson Backgrounder on pharmacogenomics for the pharmaceutical and biotechnology industries: basic science, future scenarios, policy directions - final report 2007 University of Washington Seattle, WA
2. Secretary's Advisory Committee on Genetics, Health and Society Realizing the potential of pharmacogenomics: opportunities and challenges 2008 Department of Health and Human Services Washington, DC
3. C. McCabe, K. Claxton, A. O'Hagan Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursement Int J Technol Assess 24 2008 140 145 (Pubitemid 351519511)
4. UK Pharmacogenetics Study Group Policy issues in pharmacogenetics: policy briefing from the UK Pharmacogenetics Study Group 2006 UK Pharmacogenetics Study Group Sussex, York
5. US Food and Drug Administration (FDA) Guidance for industry and FDA staff: pharmacogenetic tests and genetic tests for heritable markers 2007 US Food and Drug Administration Silver Spring, MD
6. L. Garrison, M.J. Finley Austin The economics of personalized medicine: a model of incentives for value creation and capture Drug Inf J 41 2007 501 509
7. S.D. Ramsey, D.L. Veenstra, L.P. Garrison Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests Am J Manag Care 12 2006 197 202
8. L. Billingham, D. Stocken, S. Collins Trial designs to assess biomarkers in clinical practice Presented at the International Society for Clinical Biostatistics Annual Conference Prague, Czech Republic August 24, 2009
9. President's Council of Advisors on Science and Technology Priorities for personalized medicine 2008 Executive Office of the President of the United States Washington, DC
10. Centers for Medicare & Medicaid Services National coverage determination (NCD) for pharmacogenomic testing for warfarin response (90.1) www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId= 333&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType= Final&s=All&KeyWord=warfarin&KeyWordLookUp=Title& KeyWordSearchType=And&bc=gAAAACAAAAAA& [Accessed August 8, 2011]
11. J.J. Carlson, S.D. Sullivan, L.P. Garrison Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers Health Policy 96 2010 179 190
12. D.L. Veenstra, J.A. Roth, L.P. Garrison A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice Genet Med 12 2010 686 693
13. National Institute for Health and Clinical Excellence Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer 2006 National Institute for Health and Clinical Excellence London
14. Technology Evaluation Centre CYP2D6 pharmacogenomics of tamoxifen treatment TEC Assessment Program 23 2008 1 32
15. M.P. Goetz, A. Kamal, M.M. Ames Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response Clin Pharmacol Ther 97 2008 30 39
16. T. Terasawa, I. Dahabreh, P.J. Castaldi, T.A. Trikalinos Systematic reviews on selected pharmacogenetic tests for cancer treatment: CYP2D6 for tamoxifen in breast cancer, KRAS for anti-EGFR antibodies in colorectal cancer, and BCR-ABL1 for tyrosine kinase inhibitors in chronic myeloid leukemia Agency for Healthcare Research and Quality Technology Assessment Report June 7, 2010 www.cms.gov/DeterminationProcess/downloads/id76TA.pdf [Accessed August 8, 2011]
17. D.F. Hayes, V. Stearns, J. Rae, D. Flockhart A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients? J Natl Cancer Inst 100 2008 610 613
18. M.J. Higgins, J.M. Rae, D.A. Flockhart Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Comp Canc Netw 7 2009 203 213
19. US Federal Drug Administration (FDA) Summary minutes of the advisory committee pharmaceutical science clinical pharmacology subcommittee www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4248m1.pdf October 1819, 2006 [Accessed August 8, 2011]
20. Pharmacovigilance Working Party (PhVWP) September 2010 plenary meeting report www.ema.europa.eu/docs/en-GB/document-library/Report/2010/10/WC500097444. pdf [Accessed August 8, 2011]
21. N. Fleeman, C. Mcleod, A. Bagust The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation Health Technol Assess 14 2010 1 157
22. D.B. Matchar, M.E. Thakur, I. Grossman Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Number 146 Agency for Healthcare Research and Quality Technology Assessment. January 2007 www.ahrq.gov/downloads/pub/ evidence/pdf/cyp450/cyp450.pdf [Accessed August 8, 2011]
23. ATAC Trialists' Group Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
24. M.P. Goetz, S.K. Knox, V.J. Suman The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 2007 113 121 (Pubitemid 47555336)
25. A. Eisen, M. Trudeau, W. Shelley Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review Canc Treat Res 34 2008 157 174
26. J.N. Ingle, V.J. Suman, J.A. Mailliars Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer North Central Cancer Treatment Group Trial 89-30-52 Breast Cancer Res Treat 98 2006 217 222 (Pubitemid 44050772)
27. S.A. Nowell, J. Ahn, J.M. Rae Association of genetic variation in tamoxifen-metabolising enzymes with overall survival and recurrence of disease in breast cancer patients Breast Cancer Res Treat 91 2005 249 258 (Pubitemid 40903087)
28. P. Wegman, S. Elingarami, J. Carstensen Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Canc Res 9 2007 R7
29. R. Ferraldeschi, S.J. Howell, A.M. Thompson, W.G. Newman Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen J Clin Oncol 28 2010 e584 e585
30. R.S. Punglia, H.J. Burstein, E.P. Winer, J.C. Weeks Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modelling analysis J Natl Cancer Inst 9 2008 642 648
31. D. Hind, S. Ward, E. De Nigris Hormonal therapies for early breast cancer: systematic review and economic evaluation Health Technol Assess 11 2007 iii152
32. R. Mansel, G. Locker, L. Fallowfield Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', tamoxifen alone or in combination) trial Br J Cancer 97 2007 152 161 (Pubitemid 47057463)
33. B.E. Hillner Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Cancer 101 2004 1311 1322 (Pubitemid 39180386)
34. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100 month analysis of the ATAC trial Lancet Oncology 9 2007 45 53
35. UK National Statistics Cancer statistics, registrations: registrations of cancer diagnosed in 2005, England 2008 Office for National Statistics Newport, UK
36. Arimidex: anastrozole tablets, prescribing information Revised April 2011 http://www1.astrazeneca-us.com/pi/arimidex.pdf [Accessed October 25, 2011]
37. C. Kamby, L. Sengelov Pattern of dissemination and survival following isolated loco-regional recurrence of breast cancer Breast Cancer Res Treat 45 1997 181 192 (Pubitemid 27399966)
38. J. Chang, G.M. Clark, D.C. Allred Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor Cancer 97 2003 545 553 (Pubitemid 36125831)
39. Government Actuary's Department Interim life tables 200406 http://www.gad.gov.uk/Demography%20Data/Life%20Tables/historic-interim-life- tables.html [October 25, 2011]
40. M. Lidgren, M. Wilking, B. Jonsson, C. Rehnberg Health related quality of life in different states of breast cancer Qual Life Res 16 2007 1073 1081 (Pubitemid 47174889)
41. V. Brennan, S. Wolawacz A systematic review of breast cancer utility weights Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 13th Annual International Meeting Toronto, Ontario, Canada May 37 2008
42. National Institute for Health and Clinical Excellence (NICE) Guide to the methods of technology appraisal 2008 National Institute for Health and Clinical Excellence London
43. Department of Health National schedule of reference costs 200607 for NHS trusts and PCTs combined 2008 National Health Service London
44. Joint Formulary Committee British National Formulary 54 2007 British Medical Association and Royal Pharmaceutical Society of Great Britain London
45. J. Karnon Cost-utilty analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasiver breast cancer: the UK perspective Eur J Health Econ 9 2008 17 83
46. Personal Social Services Research Unit Unit costs of health and social care 2007 Personal Social Services Research Unit, University of Kent Kent, UK
47. Mondaq, generics web, Australia: Drug in focus: Anastrozole http://www.mondaq.com/australia/article.asp?articleid=110946 October 2010 [Accessed October 25 2011]
48. IHS Global Insight Pharmac to apply reference pricing to aromatase inhibitors, aims for US$7.5mil. saving over five years www.ihsglobalinsight.com/SDA/SDADetail17960.htm December 3, 2009 [Accessed October 31, 2010]
49. K. Claxton, J. Posnett An economic approach to clinical trial design and research priority-setting Health Econ 5 1996 513 524
50. Z. Philips, K.P. Claxton, S. Palmer Priority setting for research in health care: an application of value of information analysis to glycoprotein IIb/IIIa antagonists in non-ST elevation acute coronary syndrome Int J Technol Assess 22 2006 379 387 (Pubitemid 44469445)
51. A. Brennan, S. Kharroubi, A. O'Hagan, J. Chilcott Calculating partial expected value of perfect information via Monte Carlo sampling algorithms Med Decis Making 27 2007 448 470 (Pubitemid 47106943)
52. R Development Core Team R: A language and environment for statistical computing 2008 R foundation for Statistical Computing Vienna, Austria
53. M.J. Bijl, R.H. van Schaik, L.A. Lammers The CYP2D6 *4 polymorphism affects breast cancer survival in tamoxifen users Breast Cancer Res Treat 118 2009 125 130
54. P. Wegman, L. Vainikka, O. Stal Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients Breast Canc Res 7 2005 R284 R290
55. Y. Xu, Y. Sun, L. Yao Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment Ann Oncol 19 2008 1423 1429
56. K. Kiyotani, T. Mushiroda, M. Sasa Impact of CYP2D6 *10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy Cancer Sci 99 2008 995 999 (Pubitemid 351997603)
57. BIG 198 Collaborative Group A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757
58. J.M. Rae, S. Drury, D.F. Hayes Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial Presented at the San Antonio Breast Cancer Symposium, S1-7 December 9, 2010
59. B. Leyland-Jones, M.M. Regan, M. Bouzyk Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial Presented at the San Antonio Breast Cancer Symposium, S1-8 December 9, 2010
60. S. Pal CYP2D6 testing falls short as predictor of adjuvant tamoxifen efficacy www.cancernetwork.com/conference-reports/sabcs2010/content/article/ 10165/1756542 December 13, 2010 [Accessed August 8, 2011]